Live Analyst Rating Changes 54325 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Ami Fadia
NDM

Ami Fadia

Needham
Wall Street Analyst
★★★☆☆
#2060
on 13Foresight · ranked by our own returns
49%
Success Rate
+1.9%
Average Return
45 of 91 calls profitable · -1.1% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 49% of Ami Fadia's ratings turned a profit when each position was held for 1 year — averaging +1.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

165 Buy 15 Hold 0 Sell
Ami's Stock Coverage 30 ratings · 2026-11-04
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
BIIB
Biogen
 Oct 29, 2026 BUY Strong Buy
+6.6% avg upside
53 analysts
$290.00
14.38% Upside
 +1.9% ·
HRMY
Harmony Biosciences Holdings
 Oct 19, 2026 BUY Strong Buy
+27.3% avg upside
14 analysts
$50.00
28.93% Upside
 -1.4% ·
ALKS
Alkermes
 Oct 19, 2026 BUY Strong Buy
-3.4% avg upside
34 analysts
$62.00
36.70% Upside
 +4.5% ·
ACAD
ACADIA Pharmaceuticals
 Oct 19, 2026 BUY Strong Buy
+71.5% avg upside
43 analysts
$35.00
69.97% Upside
 +4.0% ·
JAZZ
Jazz Pharmaceuticals
 Oct 16, 2026 BUY Strong Buy
+16.2% avg upside
36 analysts
$310.00
43.49% Upside
 +9.2% ·
NBIX
Neurocrine
 Oct 16, 2026 BUY Strong Buy
+27.3% avg upside
37 analysts
$204.00
39.71% Upside
 +22.4% ·
RVMD
Revolution Medicines
 Oct 15, 2026 BUY Strong Buy
+8.2% avg upside
36 analysts
$275.00
43.70% Upside
 +5.2% ·
AXSM
Axsome Therapeutics
 Oct 15, 2026 BUY Strong Buy
+63.9% avg upside
30 analysts
$268.00
85.53% Upside
 -14.6% ·
LBRX
LB Pharmaceuticals, Inc.
 Oct 02, 2026 BUY Strong Buy
+47.7% avg upside
11 analysts
$68.00
71.31% Upside
 +7.3% ·
PRAX
Praxis Precision Medicines
 Sep 24, 2026 BUY Strong Buy
+99.2% avg upside
25 analysts
$582.00
103.60% Upside
 -2.8% ·
DFTX
Definium Therapeutics
 Sep 14, 2026 BUY Strong Buy
+48.7% avg upside
24 analysts
$66.00
81.70% Upside
 -19.3% ·
MPLT
MapLight Therapeutics, Inc.
 Aug 31, 2026 BUY Strong Buy
+288.1% avg upside
14 analysts
$43.00
467.37% Upside
 -48.3% ·
NMRA
Neumora Therapeutics, Inc.
 Aug 14, 2026 BUY Buy
+1957.6% avg upside
11 analysts
$5.00
1261.69% Upside
 -68.1% ·
COGT
Cogent Biosciences
 Aug 11, 2026 HOLD Strong Buy
+24.4% avg upside
26 analysts
 — -18.6% ·
GHRS
GH Research
 Aug 06, 2026 BUY Strong Buy
+90.0% avg upside
12 analysts
$39.00
86.96% Upside
 -34.0% ·
IMRX
Immuneering
 Aug 05, 2026 BUY Strong Buy
+379.3% avg upside
12 analysts
$18.00
380.54% Upside
 -14.3% ·
BCYC
Bicycle Therapeutics
 Jul 30, 2026 BUY Strong Buy
+557.2% avg upside
21 analysts
$14.00
282.55% Upside
 -10.6% ·
ES:PHM
Pharma Mar SA
 Apr 25, 2025 BUY Strong Buy
+62.2% avg upside
4 analysts
$108.00
60.06% Upside
 +33.1% ·
MTRX
Matrix Service Company
 Dec 14, 2022 HOLD Strong Buy
+148.0% avg upside
6 analysts
 — +67.9% ·
XERS
Xeris Pharmaceuticals
 Mar 10, 2021 BUY Strong Buy
+3.9% avg upside
10 analysts
$7.00
34.74% Downside
 +291.7% ·
ARDX
Ardelyx
 Mar 08, 2021 BUY Strong Buy
+324.3% avg upside
21 analysts
$15.00
395.14% Upside
 -85.5% ·
VTRS
Viatris
 Mar 02, 2021 HOLD Buy
+25.5% avg upside
22 analysts
 — -24.3% ·
PRGO
Perrigo Company
 Mar 01, 2021 BUY Hold
+333.3% avg upside
20 analysts
$63.00
299.29% Upside
 -9.9% ·
AMRX
Amneal Pharmaceuticals
 Feb 26, 2021 HOLD Strong Buy
-10.1% avg upside
19 analysts
$6.00
72.05% Downside
 -14.8% ·
AMRN
Amarin
 Feb 25, 2021 BUY Buy
-28.6% avg upside
18 analysts
$16.00
32.19% Upside
 -52.9% ·
PCRX
Pacira Pharmaceuticals
 Feb 25, 2021 HOLD Hold
+11.8% avg upside
23 analysts
$75.00
106.07% Upside
 -9.8% ·
OBSEF
ObsEva
 Jan 11, 2021 BUY Buy
+10799900.0% avg upside
8 analysts
$5.00
4999899.97% Upside
 · ·
HRTX
Heron Therapeutics
 Dec 02, 2020 BUY Strong Buy
+10208.0% avg upside
21 analysts
$24.00
8542.51% Upside
 · ·
ITRMF
Iterum Therapeutics
 Oct 01, 2020 HOLD Buy
+716666566.7% avg upside
5 analysts
$1.50
149999899.92% Upside
 · ·
TRVI
Trevi Therapeutics
 Aug 14, 2020 BUY Strong Buy
+75.4% avg upside
18 analysts
$9.00
33.69% Downside
 -65.5% ·
🔒 25 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Ami Fadia — Frequently Asked Questions
How accurate are Ami Fadia's stock ratings?
Based on the calls 13Foresight could measure, about 49% of Ami's ratings were profitable over a one-year hold, with an average return of +1.7% per rating, or -1.0% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Ami ranked on 13Foresight?
Ami Fadia is currently ranked #2060 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Ami cover?
Ami most recently has ratings on BIIB, HRMY, ALKS, ACAD, JAZZ, NBIX, RVMD, AXSM, LBRX, PRAX, DFTX, MPLT and 18 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.